ATS 2024 Final Program

Click on the session title to view the speakers

338

WEDNESDAY • MAY 22

CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

D92 BOOKENDS: ILAS TO PPF 11:00 a.m. - 1:00 p.m.

D93 LOOKING BEYOND THE LUNGS: COPD AND COMORBIDITIES 11:00 a.m. - 1:00 p.m. San Diego Convention Center Room 6B (Upper Level) 11:00 Data-driven Identification and Investigation of Comorbidity Profiles in Patients With Chronic Obstructive Pulmonary Disease: A Multicohort Study 11:12 Impact of Weight Loss Over 5 Years on Respiratory Morbidity in Obese COPD Participants From COPDGene 11:24 Nocturnal Hypoxemia Is Associated With Sarcopenia in COPD Patients 11:36 Comparison of 3D Paraspinal Muscle Volume and 2D Paraspinal Muscle Area Measurements Along the Thoracic Spine From Chest CT Images in COPD: Findings From the CanCOLD Study 11:48 Differentially Co-expressed Myofiber Transcripts Associated With Abnormal Skeletal Muscle Fiber Proportion in COPD 12:00 Lung-related Risk Factors for Low Bone Mineral Density in Tobacco-exposed Individuals Not Meeting Osteoporosis Screening Criteria 12:12 Sex Differences in the Association Between Iron Deficiency, Anemia, and Hospitalization Risk in COPD 12:24 Impaired Cardiac Blood Flow in Chronic Obstructive Pulmonary Disease: 4D Flow Results From the Subpopulations and Intermediate Outcome Measures in COPD and Heart Failure Study (SPIROMICS HF) 12:36 Impaired Left Ventricular Filling and All-cause Mortality in COPD 12:48 Chronic Obstructive Pulmonary Disease (COPD) Subtypes Differentially Predict Subsequent Cardiovascular Events and COPD Exacerbations: A Longitudinal Analysis of the COPDGene Study

San Diego Convention Center Room 6C-F (Upper Level)

Oral Presentations: 11:00 Development and Progression of Interstitial Lung Disease in COPDGene 11:12 Proteins Biomarkers for the Detection of Interstitial Lung Abnormalities in a High-risk Cohort 11:24 Interstitial Lung Abnormalities Below Fleischner-Defined Thresholds Are Strongly Associated With Progression in Persons at Risk for Familial Pulmonary Fibrosis 11:36 Visual and Quantitative Predictors of Interstitial Lung Abnormality Progression in COPDGene 11:48 Proteomic Signature of Quantitative Interstitial Abnormalities in COPDGene and Cardia Lung Study 12:00 Endobronchial Optical Coherence Tomography as a Novel Method for In Vivo Microscopic Assessment of Interstitial Lung Abnormalities 12:12 How Should Patients With Progressive Pulmonary Fibrosis Be Identified? Consensus Findings From a Modified Delphi Study 12:24 Characterizing Progressive Pulmonary Fibrosis in a Multi-center Real World Cohort 12:36 Fibrosis Scores Per Quantitative High-resolution Computed Tomography at Baseline and the Change Over One Year Predict Subsequent Progressive Pulmonary Fibrosis at 24 Months 12:48 Test Performance Characteristics of Proposed Criteria for Progressive Pulmonary Fibrosis

ATS 2024 • San Diego, CA